Propanc Biopharma Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Mar 2026
Net Income -$17.3MTTM through 31 Mar 2026
Free Cash Flow -$4.2MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-64.7%ROE
-44.4%ROA
Balance Sheet Health
Debt / Equity0.05x
Current Ratio2.37x
Net Debt$76.6K
Cash & Equivalents$443.7K
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.